soluble tumor necrosis factor p75 receptor
Etanercept, a bioengineered fusion protein derived from the human soluble tumor       necrosis factor p75 receptor, recently has been approved for use in patients with       refractory RA.
Etanercept, a bioengineered  @OBJECT$   @PREDICAT$  from the human  @SUBJECT$ , recently has been approved for use in patients with       refractory RA.